Lung Cancer

Notably, synthetic PAMP administration recapitulates these anti-tumor effects, effectively reducing intracellular proline levels and impairing tumor progression in cellular and animal models. Together, our findings uncover a previously uncharacterized lncRNA-encoded micropeptide that orchestrates proline metabolic reprogramming to restrain LUAD development, offering new opportunities for metabolic intervention in precision oncology.

This multi-omics MR framework identifies genes whose genetically predicted expression is associated with increased or decreased lung cancer risk and may help prioritize candidate targets for future lung cancer drug development.

P=N/A, N=40, Recruiting, Istanbul University | Active, not recruiting --> Recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jun 2026 --> Sep 2026

P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028

P3, N=430, Not yet recruiting, PrECOG, LLC.

P=N/A, N=400, Recruiting, Sheba Medical Center

P2, N=32, Recruiting, Nanfang Hospital, Southern Medical University

This first documented case demonstrates the therapeutic efficacy of crizotinib in ALK-IR rearranged NSCLC, emphasizing the importance of comprehensive molecular profiling in guiding precision oncology.

In vitro, LEPR knockdown significantly inhibited proliferation and invasion while promoting apoptosis in LUSC cells. These findings suggest that LEPR may play a critical role in the development and progression of LUSC, providing a potential target for therapeutic intervention.

A 77-year-old woman with stage IV serous endometrial carcinoma presented 24 days after a single dose of carboplatin, paclitaxel, and pembrolizumab, with progressive weakness, ptosis, diplopia, and respiratory compromise...She was treated with pulse corticosteroids and plasma exchange (PLEX), with rituximab added after the second session for an inadequate response. Persistent myocarditis with sustained troponin elevation prompted further escalation to abatacept and ruxolitinib...The case is distinguished by refractory disease requiring four sequential lines of immunosuppression, concurrent immune-mediated hepatitis and thyroiditis, and a seronegative myasthenia gravis profile, consistent with the more heterogeneous, non-antibody-mediated mechanisms increasingly recognized in ICI-induced disease. It informs treatment escalation in refractory cases and underscores three principles essential to managing this high-mortality syndrome: early recognition, systematic screening for all syndromic components once any one is identified, and timely escalation through multiple lines of immunosuppression when disease proves refractory.

Our findings define GPNMB-ECD-driven resistance as a novel paradigm in NSCLC and identify a viable precision therapeutic strategy to overcome it.

Specific DEGs for NSCLC are present in platelets, including HSP90AB1, NPM1, CD44, and CD74, which may play a role in the early stages of NSCLC development. These genes exhibit a specific expression pattern, characterized by downregulation in early-stage (I and II) NSCLC, indicating their potential as biomarkers for early screening and diagnosis of NSCLC.